the replication and repair of mitochondrial DNA (Chan & Copeland, 2009 ) and mutation in the POLG may cause various clinical manifestations, including parkinsonism (Miguel et al., 2014) , epilepsy (Stricker et al., 2009; Stumpf, Saneto, & Copeland, 2013) , cerebellar ataxia (Stricker et al., 2009; Stumpf et al., 2013) , and progressive external ophthalmoplegia (Luoma et al., 2004; Miguel et al., 2014) . R964C, a missense substitution POLG mutation, was considered to be related to manifestations of the central nervous system other than typical PD. Herein, we report the first case of a patient with young-onset PD (YOPD) carrying both POLG R964C and GBA L444P mutations.
| C A S E PRE S ENTATI ON
A man (current age: 59 years), without any underlying disease, presented with a right-hand tremor at the age of 39 years, followed by loss of facial expression, slow movement, rigidity, and postural instability. He also had rapid eye movement sleep behavior disorder (RBD), but no hyposmia or orthostatic dizziness. At the age of 45 years, his neurological examination revealed free ocular movement, no ptosis, and normal deep tendon reflex. He had right-side predominant rigidity, bradykinesia, mild neck dystonia, and festinating gait.
He generally responded well to levodopa. His Unified Parkinson Disease Rating Scale (UPDRS) III scores revealed more than 50% improvement under a levodopa equivalent dose of 790 mg. He then developed motor fluctuation and levodopa-induced dyskinesia after 7 years of symptom onset. At the age of 58 years, he demonstrated progressive cognitive decline, visual hallucination, and was required to live in a nursing home. His Mini Mental State Examination score was 10 and his Clinical Dementia Rating was 2. We obtained patient's serum lactate and pyruvate level and all revealed normal. Nerve conduction study showed right deep peroneal motor axonal neuropathy and right ulnar nerve neuropathy cross elbow, which suggested an entrapment neuropathy. Eletroencephalogram revealed no epileptiform discharge. His father was diagnosed as having PD, along with type 2 diabetes mellitus, at the age of 70 years; his neurological examination revealed resting tremor, rigidity, and bradykinesia on the left side, all of which diminished after levodopa treatment. He had We could not obtain his mother's DNA sample because the patient had not been in contact with his mother and sister for many years. His younger brother died in a traffic accident without any history of parkinsonian symptoms. The rest of his family members did not have any extrapyramidal symptom, epilepsy, myopathy, or ataxia. Figure 1 presents the family pedigree of the patient's family.
Genomic DNA was extracted from peripheral venous blood lymphocytes of the patient and his father. Next, multiplex ligationdependent probe amplification was used to detect large deletions or duplication in the DNA (Jeuken, Cornelissen, Boots-Sprenger, Gijsen, & Wesseling, 2006) . We then used target exome sequencing with a TruSeq Custom Amplicon Low Input panel (Illumina) to determine the 51 PD-causative genes mutation sites in patients (Deng et al., 2018; Lill, 2016; Puschmann, 2017) . Target regions of patients' blood genomic DNA were amplified with specific primers, ligated of adaptors to the amplified PCR products, and finally generated the were performed to detect amino acid substitutions affecting protein function. In addition, to determine potential candidate genes, we assessed the frequency of the variants in the general population (Exome Aggregation Consortium, dbSNP, 1000 Genomes Project).
We considered variants with a minor allele frequency of ≤0.1% (rare variants). The mutation was classified as a pathogenic mutation if previous literature reported it as causative.
We confirmed the presence of heterozygous missense substitu- mutation is categorized as a likely pathogenic variant for PD according to the scoring rule (Richards et al., 2015) . Moreover, GBA L444P is categorized as a pathogenic gene in the ClinVar database.
| D ISCUSS I ON
Thus, our patient and his father demonstrated a typical presentation of idiopathic PD, with two mutation sites in GBA and POLG.
GBA L444P is a known risk factor for PD; in a study, it was shown to increase PD risk by 10 times (Sidransky et al., 2009) . POLG mutations are linked to a wide range of systemic or neurological diseases (Stumpf et al., 2013) . Although this gene mutation could rarely lead to parkinsonism, R964C has never been reported in association with parkinsonism thus far.
POLG mutation damages mitochondrial DNA (mtDNA), which lead to complex I respiratory chain dysfunction and depletion of mtDNA (Reeve et al., 2008; Stricker et al., 2009) . POLG contains three domains: exonuclease (exo), linker region, and polymerase (pol; Figure 4 ) (Luoma et al., 2007) . Table 1 Luoma et al., 2004; Tzoulis et al., 2013) .
The R964C mutation is located in the pol domain (Figure 4 ).
Four studies have mentioned R964C mutation so far (Table 2) .
Homozygous R964C mutation can present as early ovarian failure or nucleotide reverse transcriptase inhibitor toxicity when anti-human immunodeficiency virus-1 medication is taken (Bailey, Kasiviswanathan, Copeland, & Anderson, 2009; Chen et al., 2018; Yamanaka et al., 2007) . In two other studies, both compound heterozygous mutations at R964C and A862T were identified and revealed to be associated with ataxia, epilepsy, and intellectual disability (Table 2 ) (Stricker et al., 2009; Wong et al., 2008) .
According to its biochemical effect, R964C missense mutation can significantly reduce the catalytic efficiency compared with its wild type (Bailey et al., 2009) . The recombinant R964C Pol γ activity had only 14% polymerase activity compared to Wide type.
In the presence of nucleoside reverse transcriptase inhibitor, both heterozygously and homozygously harboring mutant R964C Pol γ lymphoblastoid cell lines contained significantly reduced mtDNA levels, compared with those wild type Pol γ (Yamanaka et al., 2007) .
On the other hand, GBA mutation is known as loss of lysosomal hydrolase glucocerebrosidase (GCase) activity causing impairment of the autophagy lysosome pathway. Dysfunction of the mitophagy can be caused by impairment of autophagy lysosome pathway (Gegg & Schapira, 2016; Kim, Rodriguez-Enriquez, & Lemasters, 2007) . In animal model, heterozygous GBA L444P mutation mice exhibited reduction in GCase activity and impairment autophagic delivery of mitochondria to lysosomes and mitochondrial priming dysfunction (de la Mata et al., 2015; Li et al., 2019) .
Moreover, accumulating evidence has indicated that harboring more than two mutational loci in two alleles may cause a synergetic effect, leading to early neurodegeneration (Cady et al., 2015; Giri, Zhang, & Lü, 2016) . Also, polygenic factors contribute to the impairment of mitochondrial replication and repair may result in PD (Gaare et al., 2018) . We suspect that these two gene mutations could both influence repairing mitochondria and increase oxidative stress causing early neurodegeneration.
In our patient's family, only one patient developed YOPD, whereas his father developed late-onset PD. No literature has reported PD in POLG R964C mutation. Furthermore, the same mutations could reveal variable presentations, suggesting that epigenetic or environmental factors, as well as other modifiers may influence the clinical manifestation.
| CON CLUS ION
We reported a first familial PD of combined POLG R964C and GBA L444P mutations. This finding extends our understanding of the PD genotype-phenotype correlation.
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